(Q36577428)

15 August 2017

1 reference

title

Mechanisms and consequences of fibrosis in systemic sclerosis (English)

1 reference

15 August 2017

Christopher P Denton

1

1 reference

PubMed ID

16932673

15 August 2017

Carol M Black

series ordinal

2

1 reference

PubMed ID

16932673

15 August 2017

David J Abraham

series ordinal

3

1 reference

15 August 2017

1 March 2006

1 reference

Nature Clinical Practice Rheumatology

15 August 2017

1 reference

15 August 2017

2

1 reference

15 August 2017

3

1 reference

15 August 2017

134-144

1 reference

Novel fibrogenic pathways are activated in response to endothelial apoptosis: implications in the pathophysiology of systemic sclerosis

15 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

7 January 2021

Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

7 January 2021

A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

7 January 2021

The vasculopathy of Raynaud's phenomenon and scleroderma

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

7 January 2021

Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

7 January 2021

In vivo analysis of the apoptosis-inducing effect of anti-endothelial cell antibodies in systemic sclerosis by the chorionallantoic membrane assay

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

7 January 2021

Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

7 January 2021

Circulating endothelial cells as a marker of ongoing vascular disease in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

7 January 2021

Paclitaxel modulates TGFbeta signaling in scleroderma skin grafts in immunodeficient mice.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

7 January 2021

The TNF-863A allele strongly associates with anticentromere antibody positivity in scleroderma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

7 January 2021

Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

7 January 2021

Identification of novel targets in scleroderma: update on population studies, cDNA arrays, SNP analysis, and mutations

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

7 January 2021

Clinical significance of anti-topoisomerase I antibody levels determined by ELISA in systemic sclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

7 January 2021

IgG antiendothelial cell autoantibodies from scleroderma patients induce leukocyte adhesion to human vascular endothelial cells in vitro. Induction of adhesion molecule expression and involvement of endothelium-derived cytokines

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

7 January 2021

Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

7 January 2021

Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

7 January 2021

Constitutive phosphorylation of focal adhesion kinase is involved in the myofibroblast differentiation of scleroderma fibroblasts

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

7 January 2021

Cellular origins of fibroblasts: possible implications for organ fibrosis in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

7 January 2021

Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

7 January 2021

Transforming growth factor-beta and connective tissue growth factor: key cytokines in scleroderma pathogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

7 January 2021

Connective tissue growth factor: a new and important player in the pathogenesis of fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

7 January 2021

Endothelin and endothelin receptor antagonists in systemic rheumatic disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

7 January 2021

Monocyte chemoattractant protein 3 as a mediator of fibrosis: Overexpression in systemic sclerosis and the type 1 tight-skin mouse

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

7 January 2021

Identification of an IL1A gene segment that determines aberrant constitutive expression of interleukin-1 alpha in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

7 January 2021

Impaired Smad7-Smurf-mediated negative regulation of TGF-beta signaling in scleroderma fibroblasts

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

7 January 2021

Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

7 January 2021

High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

7 January 2021

Clinical trials: types, design, and end-points

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

7 January 2021

Dosage effects of orally administered bovine type I collagen on immune function in patients with systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

7 January 2021

Haematopoietic stem cell transplantation for the treatment of systemic sclerosis and other autoimmune disorders

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

7 January 2021

CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

7 January 2021

Clinical aspects of lung involvement: lessons from idiopathic pulmonary fibrosis and the scleroderma lung study

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

7 January 2021

Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

7 January 2021

Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

7 January 2021

Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

7 January 2021

The natriuretic peptides and their role in disorders of right heart dysfunction and pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

7 January 2021

N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

7 January 2021

Pulmonary Arterial Hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

7 January 2021

A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

7 January 2021

Acute renal failure occurring in scleroderma treated with cyclosporin A: a report of three cases

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

7 January 2021

Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

7 January 2021

Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

7 January 2021

Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

7 January 2021

Severe gastrointestinal involvement in systemic sclerosis: report of five cases and review of the literature

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

7 January 2021

Sacral nerve stimulation for faecal incontinence due to systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

7 January 2021

Argon plasma coagulation for treatment of watermelon stomach

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0115

7 January 2021

Identifiers

DOI

10.1038/NCPRHEUM0115

1 reference

15 August 2017

1 reference

PubMed ID

16932673